Fatima Karzai, MD, on Prostate Cancer: Treatment Study Results
2018 Genitourinary Cancers SymposiumFatima Karzai, MD, of the National Institutes of Health, discusses phase II findings on olaparib and durvalumab in metastatic castration-resistant prostate cancer in an unselected population (Abstract 163).
Related Videos
Laurence Albiges, MD, PhD, on RCC: Results From the NIVOREN GETUG-AFU 26 Trial
Laurence Albiges, MD, PhD, of the Gustave Roussy Cancer Centre, discusses study findings on the safety and efficacy of nivolumab in metastatic renal cell carcinoma (Abstract 577).<...
Jeffrey M. Holzbeierlein, MD, on Penile, Urethral, and Testicular Cancers: Abstract Roundup
Jeffrey M. Holzbeierlein, MD, of the University of Kansas Medical Center, summarizes key abstracts on long-term sexual function in germ cell tumor survivors, sentinel node biopsy i...
Daniel J. George, MD, on RCC: Study Results on Adjuvant Treatment
Daniel J. George, MD, of Duke University Medical Center, discusses phase III findings on adjuvant sunitinib in patients with high-risk renal cell carcinoma, in an exploratory pharm...
John J. Coen, MD, on Bladder Cancer: Results From the NRG/RTOG 0712 Trial
John J. Coen, MD, of 21st Century Oncology, discusses phase II study findings on selective bladder preservation with twice-daily radiation plus fluorouracil/cisplatin or daily radi...
Paul L. Nguyen, MD, on Prostate Cancer: Abstract Roundup
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he chaired on prostate cancer, which included discussion of daily vs weekly image-guided radiotherapy;...
